Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 0.68 |
| ▸ | RAB9A | P51151 | 11/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12918700 | 0.87 | TDP1 (0.65) | NPC1RAB9ASMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL9422430 | 0.87 | CA1 (0.65) | NPC1RAB9AHDAC6SMN1; SMN2MAPT | |
| SCHEMBL1505173 | 0.84 | MECP2 (0.60) | NPC1RAB9AHDAC6SMN1; SMN2MAPT | |
| SCHEMBL23316878 | 0.84 | HDAC6 (0.70) | NPC1RAB9AHDAC6SMN1; SMN2KDM4E | |
| SCHEMBL29215208 | 0.84 | NPC1 (0.58) | NPC1RAB9AHDAC6SMN1; SMN2MAPT | |
| SCHEMBL12948027 | 0.84 | MAPT (0.51) | NPC1RAB9AHDAC6SMN1; SMN2MAPT | |
| SCHEMBL7323788 | 0.84 | CA1 (0.64) | NPC1RAB9ASMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL7324703 | 0.84 | MAPT (0.64) | NPC1RAB9ASMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL7321777 | 0.84 | MAPT (0.64) | NPC1RAB9AHDAC6SMN1; SMN2MAPT | |
| SCHEMBL1931179 | 0.84 | L3MBTL1 (0.52) | NPC1RAB9AHDAC6SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-7223791-B2 | Function regulator for retinoid relative receptor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-29 | — | — | US | disclosed |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | AMMENN ET AL, JOCHEN | 2005-12-08 | — | — | US | disclosed |
| EP-1505968-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040157881-A1 | Function regulator for retinoid relative receptor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1405636-A1 | FUNCTION REGULATOR FOR RETINOID RELATIVE RECEPTOR | Takeda Chemical Industries, Ltd. (JP) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003097047-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157881-A1 | Function regulator for retinoid relative receptor | RXRA, RARA, RARG | NPC1 828/4885RAB9A 1448/4885HDAC6 3795/4885 |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | MC1R, MC4R, MC5R | NPC1 457/4885RAB9A 1063/4885HDAC6 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.